Christy Swinney
Family · Big Stone Gap, VANPI 1023281508
Payments from drug & device makers
Across 249 payments — averaging $14.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$704
- Pfizer$382
- Novo Nordisk$288
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$230
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$201
- Biohaven Pharmaceuticals, Inc.$198
- plus $2K from 29 others
What the payments were for
- Food & beverage$3,672100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 53 | $704 |
| Pfizer | 29 | $382 |
| Novo Nordisk | 27 | $288 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 13 | $230 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 13 | $201 |
| Biohaven Pharmaceuticals, Inc. | 13 | $198 |
| Abbott | 9 | $163 |
| AstraZeneca | 10 | $163 |
| Otsuka America Pharmaceutical, Inc. | 8 | $130 |
| Axsome Therapeutics, Inc. | 7 | $128 |
| Amgen | 8 | $119 |
| Biohaven Pharmaceutical Holding Company Ltd. | 7 | $117 |
| Lilly USA, LLC | 6 | $107 |
| E.r. Squibb & Sons, L.L.C. | 7 | $102 |
| Novartis | 6 | $101 |
| Exact Sciences | 3 | $51 |
| Lundbeck LLC | 3 | $51 |
| Vanda Pharmaceuticals Inc. | 3 | $51 |
| Bayer | 2 | $43 |
| GSK | 3 | $39 |
| Amarin Pharma, Inc. | 2 | $37 |
| Merck | 2 | $31 |
| Nestle Healthcare Nutrition Inc. | 2 | $29 |
| Sumitomo Pharma America, Inc. | 2 | $25 |
| Daiichi Sankyo Inc. | 1 | $24 |
| Ardelyx, Inc. | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Shield Therapeutics Inc | 1 | $18 |
| Boehringer Ingelheim | 1 | $17 |
| Antares Pharma, Inc. | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Scilex Pharmaceuticals Inc. | 1 | $14 |
| Astellas Pharma US Inc | 1 | $13 |
| Eisai Inc. | 1 | $13 |
| Johnson & Johnson | 1 | $13 |
How this compares
$3,672 in reported general payments places this provider in the 90th percentile of 4,332 family providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 209 | $230,047 |
| OzempicSemaglutide | 163 | $172,031 |
| EliquisApixaban | 206 | $170,734 |
| OtezlaApremilast | 12 | $68,179 |
| TrulicityDulaglutide | 59 | $56,335 |
| LinzessLinaclotide | 59 | $52,318 |
| JanuviaSitagliptin Phosphate | 63 | $49,215 |
| JardianceEmpagliflozin | 71 | $45,503 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 48 | $40,408 |
| FarxigaDapagliflozin Propanediol | 63 | $38,488 |
| VascepaIcosapent Ethyl | 55 | $26,377 |
| MyrbetriqMirabegron | 48 | $25,892 |
| Emgality PenGalcanezumab-Gnlm | 26 | $20,245 |
| BelsomraSuvorexant | 43 | $19,252 |
| Dexlansoprazole DrDexlansoprazole | 115 | $18,526 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $107 | $286,381268 claims |
| Novo NordiskOzempic | $288 | $172,031163 claims |
| PfizerEliquis | $382 | $170,734206 claims |
| MerckJanuvia, Belsomra | $31 | $68,466106 claims |
| AmgenOtezla | $119 | $68,17912 claims |
| AbbVieLinzess, Vraylar | $704 | $67,97270 claims |
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat | $17 | $58,37097 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $39 | $53,16075 claims |
| AstraZenecaFarxiga, Symbicort | $163 | $53,087120 claims |
| Astellas Pharma US IncMyrbetriq | $13 | $25,89248 claims |
| Johnson & JohnsonXarelto | $13 | $17,95317 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $19 | $13,80526 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,332 family providers in Virginia.
Other family in Big Stone Gap
- Celeste MullinsBig Stone Gap$53K
- Andrea CottonVirginia Beach$696K
- Susan MooreWytheville$438K
- Ellen WermterCharlottesville$251K
- Dana StallingsFranklin$225K
- Jocelyn BrackettHerndon$199K
- Hochong Smith GillesRichmond$131K
- Sean OlaughlinMidlothian$110K
- Adam MedlinHampton$67K
- Casey SharpDanville$63K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.